+1-206-701-6702
+44-020-8133-4027
+050-5539-1737
+91-848-285-0837
Press Release: Anticoagulant Reversal Drugs Market to Surpass US$ 3,089.2 Million by 2028
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Anticoagulants are the drugs used for prevention of blood clotting in the patients suffering from bleeding disorders such as Hemophilia A, Hemophilia B, and Von Willebrand diseases. Vitamin K antagonists such as phenprocoumon and warfarin are few of the most commonly used oral anticoagulatory agents. Non-vitamin K antagonist oral anticoagulants (NOACs) are rivaroxaban and dabigatran. Anticoagulant reversal drugs works as reversal agents of anticoagulation and are needed due to life-threatening or uncontrolled bleeding.
The global anticoagulant reversal drugs market is estimated to be valued at US$ 1,154.3 million in 2021 and is expected to exhibit a CAGR of 15.1% over the forecast period (2021-2028).
Figure 1. Global Anticoagulant Reversal Drugs Market Share (%), By Region, 2021
The increasing prevalence of bleeding disorders is expected to drive the growth of the global anticoagulant reversal drugs market over the forecast period.
Rising prevalence of bleeding disorders such as hemophilia is expected to boost the anticoagulant therapy and thereby driving the global anticoagulant reversal drugs market growth over the forecast period. For instance, according to the Annual Global Survey’s 2019 data published by World Federation of Hemophilia, around 210,454 number of people globally were suffering from hemophilia in 2018. Among this, 173,711 and 34,289 patients accounted for Hemophilia A and Hemophilia B, respectively.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: | US$ 1,154.3 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2028 |
| Forecast Period 2021 to 2028 CAGR: | 15.1% | 2028 Value Projection: | US$ 3,089.2 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Alexion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Behring Limited, Pfizer Inc., Octapharma AG, Bausch Health Companies Inc., Amneal Pharmaceuticals Inc., Fresenius Kabi AG, Perosphere Pharmaceuticals Inc., Ferring Pharmaceuticals Inc., Midas Pharma GmbH, Healthy Life Pharma Pvt. Ltd, Pharma Cure Laboratories, AMAG Pharmaceuticals, Inc., SGPharma Pvt. Ltd., Alps Pharmaceutical Ind. Co., Ltd., and Nischi Lifesciences |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2. Global Anticoagulant Reversal Drugs Market Value (US$ Mn), By Drug Type, 2021
The increasing research and development activities for the development of novel therapeutics as an antidote of coagulant drugs is expected to drive the market growth over the forecast period.
The rising number research and development activities by the market players in order to develop novel drugs is expected to drive the growth of the global anticoagulant reversal drugs market over the forecast period.
For instance, in July 2020, Janssen Research and Development LLC initiated the Phase I clinical trial study to assess the Reversal of the Anticoagulant Effects of JNJ-70033093 by 4-Factor Prothrombin Complex Concentrate (4F-PCC) and Recombinant Human Factor VIIa (rFVIIa). The study is estimated to complete by October 2021.
Global Anticoagulant Reversal Drugs Market – Impact of Coronavirus (COVID-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020.
According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 190,169,833 cases and 4,086,000 deaths due to coronavirus disease (COVID-19) were reported till July 18, 2021, across the globe.
During this COVID-19 pandemic, pharmaceutical business, clinical tool companies, and likewise biotechnology firms are facing difficulties that are occurring from the interruption in supply chains and the demand to transform service processes. The COVID-19 pandemic has negatively impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. However, the demand for anticoagulant reversal drugs is expected to increase in this COVID-19 pandemic owing to rising demand for the anticoagulant therapy.
The COVID-19 impact on the anticoagulant reversal drugs market is expected to be positive owing to the association of COVID-19 infection with blood disorders. For instance, according to a research article published in the American Journal of Hematology, 2020, it was observed that the COVID-19 positive patients who were suffering from severe complications exhibited increased levels of protein Factor V, a blood-clotting factor. Increased levels of protein Factor V could lead to the development of blood clots in various vital organs inside the human body.
Global Anticoagulant Reversal Drugs Market - Restraint
However, recall of the drugs by the market players is the major factor restraining the global anticoagulant reversal drugs market over the forecast period. For instance, in March 2020, Dr. Reddy’s Laboratories Ltd. announced the voluntary recall of four lots (ACB902, ACB903, ACB904, and ACB905) of Phytonadione Injectable Emulsion USP, 10 mg/mL. The product is being recalled due to product complaints received due to ampules breaking and shattering, upon opening, during compounding. Phytonadione, is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX, and X when caused by Vitamin K deficiency or interference with Vitamin K activity and for anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives.
Key Players
Major players operating in the global anticoagulant reversal drugs market include Alexion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Behring Limited, Pfizer Inc., Octapharma AG, Bausch Health Companies Inc., Amneal Pharmaceuticals Inc., Fresenius Kabi AG, Perosphere Pharmaceuticals Inc., Ferring Pharmaceuticals Inc., Midas Pharma GmbH, Healthy Life Pharma Pvt. Ltd, Pharma Cure Laboratories, AMAG Pharmaceuticals, Inc., SGPharma Pvt. Ltd., Alps Pharmaceutical Ind. Co., Ltd., and Nischi Lifesciences
Anticoagulants are used for treating and preventing blood clots events. Phenprocoumon and warfarin are the most commonly used oral anticoagulant agents. Phenprocoumon and warfarin are categorized as vitamin K antagonists while rivaroxaban and dabigatran are categorized as non-vitamin K antagonist oral anticoagulants (NOACs). Vitamin K antagonists work by inhibiting the enzyme vitamin K epoxide reductase which leads to blockage of the hepatic synthesis of the active, reduced form of vitamin K. This reduced form of vitamin K is required for carboxylation of protein C, protein S, and coagulation factors II, VII, IX, and X. Non-vitamin K antagonist oral anticoagulants work in a selective manner by either inhibiting factor Xa (rivaroxaban, apixaban, edoxaban) or thrombin (dabigatran). Since, NOACs have a comparatively short half-life and fewer interactions, NOACs are easier to control and administer than warfarin and do not require regular monitoring to ensure their efficacy and safety. Anticoagulant reversal drugs work opposite to that of anticoagulation drugs by canceling out its anticoagulation effects and are needed to control life-threatening bleeding.
Market Dynamics
Increasing prevalence of cardiac events such as ischemic stroke, pulmonary embolism, deep vein thrombosis, and others which require anticoagulant therapy is expected to fuel the global anticoagulant reversal drugs market. For instance, according to an article published by the National Centers for Biotechnology Information in July 2020, there is an increasing prevalence of Ischemic heart disease across the globe, as it affects 1,655 per 100,000 individuals, which may rise up to 1,845 per 100,000 individuals by the year 2030. Furthermore, according to data provided by the American College of Cardiology Foundation, it was estimated that around 1.05 million people suffered from coronary diseases in the U.S. in 2019. Moreover, according to the Centers for Disease Control and prevention (CDC) report 2020, it is estimated that more than 800,000 people in the U.S. suffer from a heart attack every year.
Rising collaboration and acquisition activities by the market players is expected to drive the global anticoagulant reversal drugs market. For instance, in April 2016, Daiichi Sankyo Company, Limited announced a clinical collaboration agreement with Portola Pharmaceuticals, Inc. for the development of andexanet alfa in Japan as an anticoagulant reversal agent for Daiichi Sankyo's Factor Xa inhibitor, LIXIANA (edoxaban).
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 32 market data tables and 21 figures on "Anticoagulant Reversal Drugs Market” - Global forecast to 2028
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Contact Us
